IL13 and metabolic dysfunction-associated steatohepatitis: This comes in alignment with previous reports, which showed the disturbed healing process in NASH contributed to fibrosis progression via chronic activation of type 2 inflammation manifested by increased serum IL-13 levels [9,10].